Back to News
Market Impact: 0.2
Pyxis Oncology Consensus Price Target Increased by 16.92% to $8.61
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
The aggregate one-year analyst price target for Pyxis Oncology was raised 16.92% to $8.61 per share from $7.37 as of August 25, 2026. The upward revision signals improved analyst expectations for the biotech company, though the article provides no operating, clinical, or financial catalyst behind the change.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PYXS0.40
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Beta Bionics prices $150M public offering at $17.25/share
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- DST Global Advisors sells $6.86m in Chime Financial stock
- Why Radiant Logistics Stock Topped the Market on Tuesday
- DST Global Advisors sells $6.86 million in Chime Financial stock